BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Deals

  Jounce Slashes 57% of Staff, Drops Assets in Stock Merger with Redx

  One day after revealing a restructuring initiative, Jounce Therapeutics announced it plans to merge its business in an all-stock deal with clinical-stage biotech Redx Pharma.

  February 23, 2023

   · 

  1 min read

   · 

  Rosemary Scott
• 

  Business

  AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases

  With more than $600 million on the line, AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics to advance three gene therapy programs for eye diseases.

  February 23, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Moderna Leans into R&D as Spikevax Sales Face Drop-Off

  Riding high on Spikevax sales, Moderna closed out 2022 with strong financials and a plan to invest heavily into R&D in 2023.

  February 23, 2023

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Drug Development

  Graphite Bio Cuts Sickle Cell Therapy, Half of Staff

  Graphite Bio is discontinuing the development of nulabeglogene autogedtemcel (nula-cel), its lead asset, and shaving off about 50% of its workforce.

  February 23, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Novartis Drops SCD Gene Therapy Program with Intellia

  Novartis has abandoned its ex vivo sickle cell disease program developed using Intellia Therapeutics’ CRISPR gene editing platform, Intellia announced Thursday.

  February 23, 2023

   · 

  2 min read

   · 

  Kate Goodwin
• Business

  LeMaitre Q4 2022 Financial Results

  LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance.

  February 23, 2023

   · 

  12 min read
• Genetown

  Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

  Akebia Therapeutics , Inc. (NASDAQ: AKBA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve Vafseo.

  February 23, 2023

   · 

  5 min read
• Business

  Penumbra, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

  Penumbra, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022.

  February 23, 2023

   · 

  19 min read
• Business

  Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (23% constant currency)

  Insulet Corporation announced financial results for the three months and full year ended December 31, 2022.

  February 23, 2023

   · 

  17 min read
• Business

  Personalis Reports Fourth Quarter and Full Year 2022 Financial Results

  Personalis, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business highlights.

  February 23, 2023

   · 

  10 min read